Features of primary and adaptive immunotherapy resistance in microsatellite instable cancers - Clinical Trial

What is the Purpose of this Study?

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

What is the Condition Being Studied?

Stage III unresectable colorectal cancer or stage IV endometrial, prostate, or gastrointestinal cancer

Who Can Participate in the Study?

Adults ages 18 and older who:
- Are diagnosed with stage III or IV endometrial, prostate, hepatobiliary, pancreatic, and gastrointestinal cancers with certain tumor mutations
- Do not have prostate tumors with small cell component
- Are not pregnant or breastfeeding

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Go through a screening period to see if you're eligible for the study
- Start participating before, during, or after treatment with standard of care immunotherapy for your cancer

If you're eligible to join, you will:
- Be monitored until you complete your immunotherapy treatment and the final blood and/or tissue samples are collected
- Provide the following depending on when you enroll in the study (before, during, or after immunotherapy):
-- Blood samples
-- Stool samples
-- Tumor tissue samples

Study Details

Full Title
FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS (PAIR-MSI)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00105726
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698